EverSource Wealth Advisors’s Dianthus Therapeutics DNTH Stock Holding History

EverSource Wealth Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.31K	Buy	34 +5	+17%	+$437	﹤0.01%	3487
2026 Q1	$2.43K	Buy	29 +3	+12%	+$174	﹤0.01%	3576
2025 Q4	$1.07K	Hold	26	–	–	﹤0.01%	3691
2025 Q3	$1.02K	Buy	+26	New	+$664	﹤0.01%	3758
2025 Q2	–	Sell	-13	Closed	-$236	–	4282
2025 Q1	$236	Buy	+13	New	+$287	﹤0.01%	3668

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

EverSource Wealth Advisors's DNTH Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Dianthus Therapeutics (DNTH) stake by 17% in Q2 2026, buying an estimated $437 and bringing the position to 34 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

EverSource Wealth Advisors first reported a position in DNTH in Q1 2025 and has held it in 5 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

EverSource Wealth Advisors held 34 shares of Dianthus Therapeutics worth $3.31K as of Q2 2026.
EverSource Wealth Advisors bought 5 Dianthus Therapeutics shares in Q2 2026, an estimated $437.
Dianthus Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3487 holding.
EverSource Wealth Advisors first reported a position in Dianthus Therapeutics in Q1 2025 and has held it in 5 quarters since.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.